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ABSTRACT 
The TAM (Tyro3, Axl, Mer) receptors tyrosine kinases together with their ligands Gas6 and 
protein S play an important role in many cellular processes such as resolution of inflammation 
and phagocytosis. Notably, they were found to have an important function in vasculature, 
acting as a pro-survival factors and regulators of angiogenesis. Nevertheless, their role in 
endothelial inflammation is still poorly understood. Conflicting conclusions have been 
published, indicating both pro and anti-inflammatory properties of TAM-mediated signaling 
in endothelium. In this study we sought to elucidate the role of these receptors in endothelial 
inflammation by measuring the levels of pro-inflammatory markers, such as cytokines and 
adhesion molecules, in response to inflammatory stimuli in TAM and TAM ligand-deficient 
human umbilical vein endothelial cells (HUVEC). We found that Axl/Gas6 signaling acts as 
a pro-inflammatory agent by promoting an increased expression of adhesion molecules and 
cytokine secretion. Conversely, we suggest anti-inflammatory tendencies of the Mer/protein S 
axis. Moreover, we demonstrate that starvation strongly upregulates Mer expression in 
HUVEC cells.  Finally, we propose that TAM receptors expression is differently regulated 
depending on cell type, as inflammatory regulators known to induce TAM-expression in 
immune cells fail to upregulate TAMs in HUVECs. Taken together, we present 
diversification and complexity of Axl and Mer receptor functions in endothelial 
inflammation, thus suggesting the need for further investigations. 
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Abbreviations and Symbols 
 
AC Apoptotic cell 
aPC Activated Protein C 
APC Antigen- presenting cell 
C4BP C4b-binding protein 
CNS The central nervous system 
DC Dendritic cell 
Dex Dexamethasone 
EC Endothelial cells 
EGF Epidermal growth factor 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence-activated cell sorting 
Gas6 Growth arrest specific gene 6 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HAEC Human aortic endothelial cells 
HUVEC Human umbilical vein endothelial cells 
ICAM-1 Intercellular adhesion molecule-1 
IFN- γ Interferon- γ 
IFNAR Type I interferon receptor 
Ig 
IL-1b 
Immunoglobulin 
Interleukin-1 beta 
IL-6 Interleukin-6 
IP Immunoprecipitation 
LG Laminin G domain 
 IV
LPS Lipopolysaccharide 
MCP-1 Monocyte chemoattractant protein-1 
NF- κB Nuclear factor-kappa B 
Pro S Protein S 
PtdSer Phosphatidylserine 
qRT-PCR Quantitative real-time polymerase chain reaction 
RCS The Royal College of Surgeons rats 
RPE Retinal pigment epithelial cell 
SHBG Sex hormone binding globulin 
siRNA Small- interfering RNA 
SIRS Systemic Inflammatory Response Syndrome 
SLE Systemic lupus erythematosus 
SOCS Suppressors of cytokine signaling proteins   
TAM RTK TKO  Tyro3, Axl, Mer receptor tyrosine kinase triple knockout  
TAM RTKs Tyro3, Axl, Mer receptor tyrosine kinases 
TLR Toll-like receptor 
TNF- Tumor necrosis factor- 
TSR Thrombin-sensitive region 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF-A Vascular endothelial growth factor A 
VEGFR2 Vascular endothelial growth factor receptor 2 
VKD Vitamin K dependent  
VSMC Vascular smooth muscle cells 
WB Western blot 
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1. INTRODUCTION 
Inflammation is a biological process, which is initiated in response to harmful stimuli. There 
are many causes of inflammation in human body, such as mechanical injuries, bacterial or 
viral infections, or chemical intoxication. Upon inflammation, the blood flow increases and 
the vessels dilate, which can be observed as a typical “redness and swelling”. In addition, 
endothelial cells produce various proteins, which promote further response and activation of 
specific immune cells, which can then migrate from the circulation into the tissue. 
Inflammation is a very complex biological process, and studying mechanism regulating this is 
crucial for the development of various pharmaceuticals and understanding disease pathways. 
In the presented study, we put the effort to better understand this process with respect to the 
involvement of TAM receptors expressed in the endothelium. 
1.1. TAM receptors 
Receptor tyrosine kinases (RTKs) have been known to science since the 1980s, thanks to the 
work of Hunter and colleagues (5). Nevertheless, it was not until a decade later when 
Lai & Lemke described three novel genes clustered together, within the RTK family, which 
would later on be referred to as the TAM family (6). The sequence homology of these 
genes -Tyro3, Tyro7 and Tyro12- brought the attention of many research groups. Tyro3 was 
first cloned and described by Crosier et al. (7), Tyro7 by O’Bryan et al. (8) and was given the 
name Axl, originating from the Greek word anexelekto meaning uncontrolled. Finally, 
Graham et al. (9) cloned and described human Tyro12, naming it Mer, as it was found 
expressed in monocytes, epithelial and reproductive tissues. It is worth noticing that 
nomenclature can be confusing, as many groups put the effort describing these receptors 
giving them different names. However, in this work Tyro3, Axl, Mer will be used to refer to 
the particular receptors, often abbreviated as TAM receptors or TAM RTKs. 
1.1.1. The structure of TAMs 
All three TAM receptors share structural similarities as presented in Figure 1A.  They consist 
out of an extracellular, a transmembrane and a cytosolic part. The extracellular part in the 
N-terminus begins with two immunoglobulin (Ig)-like domains, which promote the 
interaction with TAM ligands. The Ig-like domains are followed by two fibronectin type 3 
domains. The extracellular and cytosolic parts are linked by a hydrophobic transmembrane 
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domain, leading to the C-terminal protein tyrosine kinase domain (8, 10, 11). It has been 
shown that binding of a ligand results in dimerization of the receptor and hence receptor 
activation, a common feature of RTKs. TAM-activation is associated with 
autophosphorylation of the tyrosine kinase domain, consequently leading to an intracellular 
signal transduction cascade (12, 13).  
The expression of these receptors varies depending on the tissue. In humans, Tyro3 is mostly 
expressed in the central nervous system (CNS) as well as in kidneys, ovaries and testes (14, 
15), whereas Axl is found ubiquitously (8). Mer expression is mostly limited to ovaries, 
prostate, lungs and kidneys as well as to a lower extent in the spleen, liver, colon and placenta 
(9, 16). However, these receptors have been described also in vascular cells, such as in 
endothelial cells and vascular smooth muscle cells (17). Moreover, the expression of TAMs in 
antigen-presenting cells, monocytes and natural killers cell determines their primary role in 
the immune system, which will be discussed further on (9, 16). Interestingly, it has been 
shown that Axl, Mer and Tyro3 can be present as both transmebrane proteins as well as 
soluble molecules in plasma (sAxl, sMer, sTyro3). Specialized metalloproteinases have been 
described, which cleave off extracellular domain of the receptors and release it to the system 
(18-20). 
1.2. TAM RTKs ligands 
Ligand binding is crucial for the activation of TAM RTKs. Two main ligands have been 
identified to date, Gas6 and protein S (21, 22). However, it is worth mentioning that recent 
studies suggest novel agonists for TAM receptors, such as Tubby, Galectin-3 and tubby-like 
protein 1 (Tulp1), activating Mer (23-25). Nevertheless, not much is known about these 
ligands, showing the need for further investigations.   
Again, Gas6 and protein S exhibit structural similarities, as presented in Figure 1B. 
Moreover, they are homologous with around 44% sequence identity (26). Both proteins are 
vitamin K dependent (VKD) with a negatively charged Gla-domain in their N -terminal end. 
It has been shown that Gla-domain containing proteins, such as Gas6 and protein S, are 
constitutively γ‐carboxylated in their Gla-domain by a vitamin K dependent γ-carboxylase 
(27). Recently, Tsou et al. showed an essential role of this modification in the full activation 
of TAMs by their ligands (28). The gamma-carboxylation may affect the folding of Gas6 and 
protein S, hence affecting their possibility to interact with TAMs. As the 
gamma-carboxylation is necessary for Gas6 and protein S to interact with negatively charged 
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phospholipids such as phosphatidylserine, the GLA-domain may also allow the ligands to 
cluster on a surface, thereby enhancing their activity (29, 30). In addition to the Gla-domain, 
TAM ligands contain a thrombin-sensitive loop, four tandem epidermal growth factor 
(EGF)-like domains and a sex hormone binding globulin (SHBG)-domain in the C-terminal 
end. The SHBG-domain includes two laminin G (LG) domains, which are involved in binding 
to the TAM receptors (26). 
1.2.1. Gas6 
Thanks to the work of Varnum et al. growth arrest specific gene 6 (Gas6) was identified as 
a ligand for Axl (22). Nevertheless, further research proves Gas6 to serve as a ligand for all 
three receptors with different affinities (Axl≥Tyro3>>Mer)(31). The structure of Gas6 
exhibits a multidomain organization with a molecular weight of 75 kDa.(32). Balogh et al. 
(33) estimated the concentration of Gas6 in human plasma to be around 13 to 23 ng/mL 
(0.16 to 0.28 nM). This amount is considered very low when compared to other VKD proteins 
involved in homeostasis. Gas6 plays an important role in many cellular processes. As 
reviewed by Laurance et al. (32) Gas6 is involved in cellular homeostasis, promoting 
leukocyte migration and sequestration as well as platelet aggregation and hematopoiesis, as 
a response to injury and inflammatory states. However, it is worth stressing that to our 
knowledge, Gas6 is always present in complex with Axl. Interestingly, the studies show that 
circulating Gas6 is bound to soluble Axl (sAxl), thereby inhibiting its function as TAM 
agonist (34). 
1.2.2. Protein S 
Protein S is a well-characterized protein mostly due to its predominant role as an 
anticoagulant, serving as a cofactor for activated Protein C (aPC) (35). Protein S-aPC 
complex is involved in the coagulation pathway, preventing thrombin formation (36).  The 
concentration of this protein in the blood stream is around 300 nM, which makes it much 
more abundant than Gas6 (37). However, it has been shown that around 60% of the 
circulating protein S is bound to the complement protein C4b-binding protein (C4BP), thus 
competing with binding to TAM receptors (38, 39). Protein S is known to be a potent Tyro3 
and Mer agonist (21), although its function as a ligand for Axl remains controversial (13).   
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1.3. TAM functions 
TAM receptors have been studied extensively throughout past decades, due to their 
abundance and significance in many processes. For that reasons, many animal models have 
been developed and carefully investigated, thus contributing to better understanding of these 
multifunctional kinases.  
1.3.1. TAM/protein S/Gas6 deficient mice models 
Lu & Lemke were first to generate triple TAM knockout mice (TAM RTK TKO) (40). TAM 
RTK TKO mice did not develop any serious abnormalities until at the age of 4-6 weeks. At 
the age of 6 months, significant abnormalities, especially concerning the immune system were 
observed. TAM knockout’s spleens and lymph nodes grew abnormally much, ranging in 
some cases up to ten times that of a wild type organ weight. High levels of antibodies against 
own tissues were detected together with elevated levels of pro-inflammatory cytokines, such 
as TNF-α and IL-6. It is worth noticing that the clearance of apoptotic cells (ACs) was 
impaired as well. Altogether, this phenotype resembles features of human autoimmune 
diseases such as systemic lupus erythematosus (SLE), psoriasis, and rheumatoid arthritis. 
Single TAM knockouts did not exhibit such dramatic phenotypes. Tyro3-/- mice suffered from 
neurological disorders, whereas Axl knockouts exhibited increased vascular permeability and 
dysfunctional vascular remodeling, indicating an important role of Axl in vascular 
inflammation (41, 42). Notably, Mer deficient mice exhibited a similar phenotype to triple 
knockouts, considering autoimmunity. Interestingly, only triple TAM knockout resulted in 
infertility, whereas double or single TAM knockout mice were both viable and fertile (41). 
Altogether, TAM mice knockout models confirm an important role of TAM receptors in 
Figure 1 The structure of TAM (Tyro3, Axl,
Mer) receptors and their ligands Gas6/
protein S. (A) The extracellular part of TAM
receptors consists out of two
immunoglobulin-like (Ig) domains, followed by
two fibronectin type 3 domains. The cytosolic
part is built out of a protein tyrosine kinase
domain. (B) The TAM ligands (Gas6/protein S)
consist out of a GLA domain in the N-terminus,
a thrombin-sensitive region (TSR), four
epidermal growth factor-like (EGF) domains and
a sex hormone-binding globulin (SHBG) in the
C-terminus with two laminin G (LG) domains
(van der Meer et al. 2014, modified) (3). 
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the AC clearance as well as in controlling immune responses (30). Protein S deficient mice 
cannot be bred due to lethal coagulopathy and severe vascular complications(35). Gas6 
knockout mice were protected against venous and arterial thrombosis, suggesting Gas6 as 
a possible therapeutic target for thrombosis (43). However, a significant role of Gas6 in 
vasculature will be a subject of further discussion.  
1.3.2. The role of TAM RTKs in the immune response 
The first indication of an important role of TAMs in the immune response came from the 
work of Camenish et al. (44). They observed that Mer knockout mice are much more sensitive 
to lipopolysaccharide (LPS)-induced endotoxin shock compared to wild type mice. This 
discovery brought the attention towards the role of TAMs in controlling the immune 
response, as the expression of Mer in macrophages, one of the main components of the 
adaptive immune response, is widely known.  Rothlin et al. have proposed a novel model of 
TAM-dependent negative regulation of the immune response (1), as presented in Figure 2. 
This model is based on the research conducted in murine-derived dendritic cells (DCs), 
specialized antigen- presenting cells (APCs), which work as a linker between innate and 
adaptive immune response. This model involves an activation of Toll-like receptors (TLRs), 
in response to pathogen encounter (45, 46). This leads to the activation of the transcription 
factor nuclear factor-kappa B (NF- κB) pathway, thereby triggering the expression of 
pro-inflammatory cytokines (47, 48). As a result, other stimulators of inflammatory response 
are activated such as type I interferon receptor (IFNAR) together with its transcription factor 
STAT1 (2, 49). This stimulates the expression of TAM receptors, which are activated as soon 
as the ligand is present. The activation of TAMs leads to the switching of the 
pro-inflammatory IFNAR/STAT1 signaling to inhibition of inflammation (1,49). As a result, 
the suppressors of cytokine signaling proteins  (SOCS1 and SOCS3) are transcribed, which 
then block TLRs, NF- κB pathway and cytokine expression, thus resulting in inhibition of 
inflammation. This model reveals a significant role of TAMs in preventing autoimmunity 
(1, 16, 50, 51). Notably, Deng et al. (52) demonstrated that mouse-macrophage derived TLRs 
down-regulate Gas6 and protein S expression, hence promoting inflammatory state. 
Altogether, the findings show the complexity of this regulation and must be further 
investigated.  
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Furthermore, TAM RTKs have an important role in phagocytosis of apoptotic cells (ACs) by 
macrophages and dendritic cells (29, 53). Briefly, this mechanism involves recognition of 
apoptotic cells through phosphatidylserines (PtdSer) displayed on the outer leaflet of the 
plasma membrane. These signals are recognized by the TAM ligands Gas6 and protein S. As 
mentioned before, N-terminal Gla domain binds to PtdSer, which is exposed on the apoptotic 
cell, thus creating “bridge” between phagocyte and apoptotic cell, leading to the TAMs 
activation (29, 54). The studies show that Mer is mainly involved in efferocytosis by 
macrophages under basal conditions (55), whereas Axl is expressed in dendritic cells, and is 
associated with inflammatory milieu (16, 56). Notably, the phagocytic properties of TAMs 
have also been observed in different cell types. Again, animal models have been extensively 
studied, providing numerous examples. One of them is the work of D’Cruz et al. (57), who 
showed that phagocytosis of outer fragments of photoreceptors by retinal pigment epithelial 
cell (RPE) is dependent on Mer. The studies were conducted in the Royal College of 
Surgeons (RCS) rats, which serve as a model of inherited blindness. As a result, the mer gene 
was mapped, by positional cloning, to the locus responsible for inherited retinal dystrophy in 
Figure 2 The key role of TAM receptors in the resolution of inflammation (murine dendritic cell
model). Toll-like receptors (TLR) become activated in response to a pathogen encounter. The signal
from TLR receptors is sent to the nucleus and transcription of pro-inflammatory cytokines including
IFN-α is initiated (black pathway). Upon secretion, IFN-α may activate the IFNAR receptor, leading to
upregulation of TAM expression (blue pathway). Upon the Gas6/protein S binding, TAMs become
activated and the transcription of SOCS1 and SOCS3 cytokine and TLR-suppressor proteins is
initiated (orange pathway). Upon silencing of cytokine production, the cell returns to the
non-inflammatory state. (Rothlin et al. 2007, modified) (1, 2). Note that some elements in the figure
were from servier.com. 
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this rat model.  Another example is the sterility of TAM triple knockout male mice. It was 
concluded that TAM receptors are expressed in Sertoli cells, which are responsible for 
phagocytosis of apoptotic germ cells in testis. The lack of TAMs completely impaired this 
function, thereby proving their role in phagocytosis (41, 58). Furthermore, one of the best 
studied functions of TAM receptors is their role in cancer. It has been shown that both TAMs 
and their ligands are overexpressed in many human cancers. They are known to promote 
tumor angiogenesis, metastasis and immunosuppressive tumor microenvironment (59). 
Loges et al. (60) have observed elevated expression of Gas6 in tumor-associated macrophages 
compared to non-tumor associated variants, thus promoting TAM activation and proliferation 
of tumor cells in mice through PtdSer-based mechanism. 
1.4. TAM RTKs in endothelium 
Endothelial cells (ECs) line the inside of the entire network of the human vascular system. 
It has been shown that an adult human body contains approximately 1× 1013 of these cells, 
which could be compared to an organ with the mass of 1 kg. The vasculature plays an 
important role in maintaining and modulating vascular tone and blood flow. Moreover, its 
role in the regulation of thrombosis, platelet adherence and inflammatory responses is of great 
importance. Chronic vascular dysfunction leads to a number of severe diseases such as 
atherosclerosis, thrombosis and Systemic Inflammatory Response Syndrome (SIRS)(4, 61). 
1.4.1. The role of TAM receptors in vasculature 
TAM receptors play a significant role in many vascular processes. It has been shown that 
TAM receptors have a significant role in angiogenesis, which is the formation of new blood 
vessels from pre-existing capillaries. The main known pro-angiogenic factor is vascular 
endothelial growth factor A (VEGF-A), which functions as a promoting agent for survival, 
proliferation, and migration of endothelial cells (68, 69). Studies in human endothelial cells 
revealed that Axl deficiency leads to the impaired cell proliferation and endothelial tube 
formation in vitro. This finding has been confirmed with the use of Axl deficient mice model, 
where blood vessel formation and functions were diminished, thereby proving the 
involvement of Gas6/Axl signaling in angiogenesis (70). Ruan et al. (71) proposed a model 
where Axl is ligand-independently activated by VEGF-A and VEGF-2, leading to the 
engagement of P13K/Akt pathway, which is crucial for VEGF-mediated angiogenesis. 
However, it is worth stressing that itself, Axl activation by Gas6 is not sufficient for the 
induction of tube formation, and to date no reports have stated pro-angiogenic functions of 
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Gas6 (71). Conversely, other study claims that Axl/Gas6 signaling is involved in hindering 
the VEGF-A-mediated angiogensis (72). Furthermore, the work of Fraineau et al. (73) proves 
a role of protein S in angiogenesis. According to the authors, protein S acts as an endogenous 
inhibitor of angiogenesis, and Mer mediates this action. They claimed the existence of protein 
S/Mer/tyrosine phosphatase SHP2 axis, which would inhibit VEGF receptor 2 (VEGFR2) 
mediated pro-angiogenic signaling pathway. This study is in agreement with Png et al.(74), 
who showed that tumor cells secrete sMer, which may block the normal proS/Mer-dependent 
inhibition of angiogenesis, thereby promoting tumor vascularization. Moreover, it has been 
shown that exogenous Gas6/Axl axis promotes pro-survival environment in endothelium, by 
acting as an antiapoptotic factor in response to TNF-α treatment (17, 75). Hasanbasic et al. 
concluded that this action is determined by the Gas6/Axl-mediated activation of survival 
pathways such as Akt phosphorylation and NF-κB (76, 77). 
Notably, angiogenesis is a key process in cancer development, thus many studies report the 
use of small-molecule inhibitors targeting Axl signaling pathway, as a promising approach in 
the treatment of cancer (70).  
1.4.2. Regulation of endothelial inflammation by TAMs 
Endothelial cells become activated as a result of pro-inflammatory stimuli such as cytokines. 
Under inflammatory conditions, an elevated surface expression of adhesion molecules and 
tissue factor is initiated, leading to activation of coagulation and platelet attachment. 
Furthermore, activated endothelium promotes leukocyte and monocyte adhesion to the 
inflammatory site, triggering the innate immune response. Adhesion molecules are one of the 
main mediating agents of this process. One of the most quickly upregulated molecules is 
E-selectin, followed by intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1). Together, adhesion molecules ensure the migration of 
leukocytes across the vasculature, which plays an important role in both chronic and acute 
inflammation. In practice, adhesion molecules serve as good markers for detecting endothelial 
inflammatory states (62, 63). Furthermore, pro-inflammatory cytokines such as tumor 
necrosis factor- (TNF-), and interleukin-6 (IL-6) have been found to trigger strong 
inflammatory response in endothelial cells, resulting in elevated expression of adhesion 
molecules and increased endothelial permeability (4, 64), Figure 3. 
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It has been observed that endothelial cells (ECs) express Axl and its ligand Gas6 (26). 
Nevertheless, whether they regulate inflammatory responses in the vasculature is still unclear, 
as contradictory findings have been reported. Tjwa et al. (65) concluded, based on a Gas6 
knockout mice model, the involvement of Gas6 in the sequestration of leukocytes on TNF- α 
activated ECs. Moreover, according to this model, Gas6 amplifies endothelial activation in 
response to the inflammatory agents as well as is involved in graft destruction of transplanted 
heart in mice. Furthermore, in vitro studies in human umbilical vein endothelial cells 
(HUVEC) indicate significant reduction of the expression of TNF- α induced ICAM-1, when 
Gas6 and Axl have been knocked down with siRNA. Altogether, this study indicates 
pro-inflammatory properties of the Axl/Gas6 system. However, according to the study of 
Avanzi et al. (66), resting ECs (such as HUVECs) produce Gas6 as a physiologic 
anti-inflammatory agent. In this model, endogenously secreted Gas6 inhibits granulocyte 
adhesion to endothelium. The authors suggest that pro-inflammatory triggers lead to the 
diminishing of endothelial Gas6 and activation of proadhesive machinery.  Furthermore, other 
animal studies indicate the role of Gas6 in promoting platelet aggregation, contributing to the 
venous and arterial thrombosis (43, 61). Interestingly, research in vascular smooth muscle 
Figure 3 Endothelial inflammation. Under basal conditions endothelial cells are involved in
ensuring a non-thrombogenic blood-tissue environment. They release a number of vasoactive
substances such as prostacyclin and nitric oxide, which prevent platelet aggregation and regulate
blood flow. Inflammatory stimuli such as histamine, thrombin, TNF-α, IL-6 or LPS activate endothelial
cells, triggering immune responses. The first line of response is expression of adhesion molecules,
such as E-selectin, ICAM-1 and VCAM-1, which promote leukocyte extravasation. As a result, the
endothelium responds with the production of various inflammatory mediators and growth factors.
Altogether, the inflammatory environment can be described as pro-thrombotic, and pro-proliferative
as it promotes platelet aggregation to the site of injury and cell growth respectively (4). TNF-α, Tumor
necrosis factor-; IL-6, Interleukin-6; MCP-1 or 2, Monocyte chemoattractant protein-1 or 2; LPS,
Lipopolysaccharide; GM-CSF, Granulocyte-macrophage colony-stimulating factor; ICAM-1,
Intercellular adhesion molecule-1; VCAM-1, Vascular cytoadhesion molecule-1.  
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cells (VSMC) reveals the role of environmental alterations such as glucose concentration in 
modulating Axl/Gas6 signaling (67).  
The presented findings show that the variation in the Gas6 concentration might influence 
TAM signaling in both immune cells (Figure 2) and in endothelium. Nevertheless, the 
outcome of the Gas6 /Axl signaling in vasculature remains unclear. 
Despite the widely discussed role of Axl/Gas6 signaling in vasculature, one cannot 
underestimate the significance of Mer and Tyro3, which needs further investigations. 
However, as mentioned before, Tyro3 is mainly expressed in the CNS (14), thus its role in 
vascular endothelium might be of lesser significance.   
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1.5. The aim of work 
The aim of this work is to elucidate the role of TAMs in inflammatory signaling in primary 
human endothelial cells by studying whether TAM activation by Gas6 and protein S affects 
the pro-inflammatory responses in endothelial cells, induced by different inflammatory 
stimuli, such as cytokines. Moreover, the role of TAMs will be studied by blocking the 
different TAM receptors and their ligands with either siRNA treatment or inhibitory 
antibodies, thereby providing information about their function in the inflammatory response. 
As readout, we will investigate the secretion of cytokines and cell surface expression of 
adhesion molecules.  
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2. MATERIALS AND METHODS 
2.1. Cell culture 
Human umbilical vein endothelial cells (HUVEC, Life Technologies) were cultured in M200 
medium (GIBCO) supplemented with low serum growth supplement (LSGS, GIBCO), 
50 U/ml penicillin and 50 μg/ml streptomycin (PS) (full/complete medium) or in serum-free 
medium (starvation medium). Cells were grown on 6- or 12- well plates or in T75 flasks 
(Thermo Scientific). Before seeding cells, culture dishes were coated with 0.1% gelatin 
(gelatin from porcine skin type A, Sigma-Aldrich). Cells were cultured in humidified 
chamber with 5% CO2 at +37 °C. The experiments were carried out on cells in passage 2-6. 
2.2. Reagents and antibodies 
Recombinant Human Tumor Necrosis Factor-alpha (TNF-α) (#PHC3016) was from GIBCO. 
Dexamethasone (#D49002) as well as lipopolysaccharide from Escherichia coli (LPS) 
(#L3024) was purchased from Sigma-Aldrich, recombinant human Interferon gamma (IFN-γ) 
(#11343534) from Immunotools. For siRNA treatment control siRNA (sc-37007), human (h) 
Axl siRNA (sc-29763), (h) Mer siRNA (sc-37127), (h) Tyro3 siRNA (sc-36438) and (h) Gas6 
siRNA (sc-35450) were from Santa Cruz Biotechnology. BSA Cohn fraction V, protease free 
(#B2000-100) was from Saveen Werner.   
Antibodies used were as follows: anti-Mer (ab52968) from Abcam, anti-Axl (AF154), 
anti-Mer  (AF891), anti-Tyro3 (AF859), anti-Gas6 (AB885), anti-VCAM-1 (FAB5649A), 
anti-ICAM-1 (BBA20), anti-E-selectin (BBA21) were from R&D Systems and anti-protein S 
(A0384) from Dako. Moreover, anti-Axl H-124 (sc-20741) and C-20 (sc-1096), anti-p-Tyr 
PY99 (sc-7020) were from Santa Cruz Biotechnology, rabbit polyclonal anti-Axl 042 (home 
made). Anti-β-Actin (A5441) was from Sigma-Aldrich. The secondary antibodies used for 
immunoblot analysis were horseradish peroxidase-conjugated anti-rabbit (P0399), anti-goat 
(P0449) and anti-mouse (P0447), all from Dako.  
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Gas6 and protein S 
Recombinant human Gas6 was expressed in Hek293 cells and purified as descried in the 
previously published method (78) with modifications. In short, the expression media 
containing recombinant human Gas6 was centrifuged at 2500 rpm, 10 minutes at 4C, and 
then filtered in order to remove any remaining debris. Next, Gas6-contaning media was batch 
purified on a DEAE Sephacel matrix (GE), followed by wash with 20 mM Tris-HCl pH 8.0, 
20 mM NaCl, and elution with a 50-500 mM NaCl gradient in 20 mM Tris-HCl, pH 8.0, 
performed on an Äkta HPLC system (GE). The fractions with Gas6 were collected, pooled 
and again purified on DEAE Sephacel, with a 20-500 mM NaCl gradient in 20 mM Tris-HCl, 
pH 8. Further, the Gas6-containing fractions were concentrated on 10 kDa MWCO spin 
columns (Amicon), according to the provided manual. Next, Gas6 was purified on a Superdex 
200 column, and subsequently eluted with 100 mM NaCl in 20 mM Tris-HCl, pH 8.0. Again, 
Gas6 fractions were collected and concentrated. Finally, 2 mg/mL BSA was added to the 
purified Gas6 and stored in aliquotes at -70C. 
Protein S was purified from human plasma according to (79) with the following additions: 
After dissolving the BaCl2-precipitate in 0.2 M EDTA containing 10 mM benzamidine and 
0.1 mM PMSF, ammoniumsulfate was added stepwise to 40% saturation and the mixture was 
incubated at +4C o/n with stirring. Precipitated proteins were removed by centrifuging the 
sample at 2400 g for 20 min at +4C. The ammoniumsulfate concentration of the supernatant 
was then increased to 67%, and the sample was stirred at +4C for 1 h to allow vitamin-K 
dependent proteins to precipitate. The precipitate was collected by centrifuging the sample at 
15 000g for 20 min at +4C and further dissolved in 0.1M sodium phosphate pH 6.0, 10 mM 
benzamidine, 0.1 mM PMSF, 1% Tween-20. The sample was then dialyzed o/n against 0.1M 
sodium phosphate pH 6.0, 10 mM benzamidine, 0.1 mM PMSF with three buffer changes. 
The sample was filtered through a 0.45 μm filter and applied to a DEAE Sephacel matrix (GE 
HEalthcare) equilibrated with 0.1M sodium phosphate pH 6.0, 10 mM benzamidine, 0.1 mM 
PMSF. The column was washed with 0.1M sodium phosphate pH 6.0, 10 mM benzamidine, 
0.1 mM PMSF, 1% Tween-20 followed by 0.1M sodium phosphate pH 6.0, 100 mM NaCl, 
10 mM benzamidine. Next, washed with 0.1 mM PMSF before eluting bound proteins with 
a linear gradient of 100-700 mM NaCl in 0.1M sodium phosphate pH 6.0, 10 mM 
benzamidine, 0.1 mM PMSF. Fractions containing free protein S were pooled and dialyzed 
against 20 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM benzamidine, 0.1 mM PMSF. 
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The sample was passed through a Blue Sepharose column (GE Healthcare) equilibrated with 
20 mM Tris-HCl pH 7.5, 1 mM EDTA, 100 mM NaCl, 10 mM benzamidine, 0.1 mM PMSF 
and the flow through containing protein S was collected. To ensure complete removal of 
C4BP-bound protein S, the flow through was passed through a 5 mL HiTrap column (GE 
Healthcare) coupled with an in-house monoclonal antibody against C4BP (MK104). 
The unbound fraction was further purified on a HiTrap-column coupled with an in-house 
monoclonal antibody against protein S (MK21). All the monoclonal antibody affinity 
columns were equilibrated with 20 mM Tris-HCl pH 7.5, 100 mM NaCl, 2 mM CaCl2, 
10 mM benzamidine before use, and bound proteins were eluted with 100 mM Glycine-HCl 
pH 2.7 into tubes containing 1M Tris-HCl pH 9.0 to neutralize the pH. The pure protein S 
was dialyzed against TBS containing 2 mM CaCl2 and stored in aliquots at -80C. 
2.3. Cytokine stimulation 
2.3.1. Acute and chronic cytokine stimulation 
HUVECs were grown until 70% confluence. In the acute stimulation model, cells were first 
washed once with DPBS for cell culture (GIBCO) then transfected with siRNA against 
Axl/Mer/Tyro3/Gas6 with the use of Oligofectamine Transfection Reagent from Invitriogen, 
according to the manual provided by the producer. After incubating for 4h in the serum-free 
conditions, the serum was added to the transfection mixes to 1% corresponding to the amount 
in full medium. After 20h incubation, the medium was changed and incubation continued for 
additional 7 hours to allow cells to recover from the transfection. After that, cells were 
washed once with DPBS and stimulated for 20 hours with 10 ng/mL TNF- α in starvation 
medium. Supernatants were collected for ELISA analysis and stored in the -20°C. Cells were 
trypsinized and FACS analysis was performed as described later on. 
In the chronic stimulation variant, cells were first pre-stimulated for 48h with 10 ng/ml TNF-α 
in complete medium, followed by wash with DPBS and transfection with siRNA against 
Axl/Mer/Tyro3. Again, serum was added to the transfection mix after 4 hours, and the 
incubation continued for 20 hours. Next, cells were washed with DPBS and stimulated for 
24 hours with 10 ng/mL TNF- α in serum-free medium, followed by FACS and ELISA 
analysis, as in the acute stimulation variant.  
2.3.2. Cell stimulation with TAM ligands and antibodies 
HUVEC cells were grown until 90% confluence. Cells were washed once with DPBS for cell 
culture, then stimulated for 20 hours with 10 ng/mL TNF- α with or without either 5 μg/mL of 
  15
anti-Axl (AF154), anti-Mer (AF891) or anti Tyro3 (AF859) in serum-free medium. In another 
variant, HUVEC cells were grown until 90% confluence. However, prior the stimulation cells 
were washed once and pre-starved for 2 hours in serum-free medium. Next, cells were 
stimulated for 20h with 10ng/mL TNF- α supplemented with either 200 ng/mL Gas6, 
5 μg/mL protein S, 2.5 μg/mL anti-Gas6 (AB885) or 50 μg/mL anti-protein S (DAKO) in 
serum-free medium. The stimulation was followed by FACS analysis for adhesion molecule 
expression as described further on.  
2.3.3. TAM upregulation upon cytokine stimulation 
HUVEC cells were grown until 90% confluence, then washed once with DPBS and 
stimulated with 10 ng/mL TNF- α in full medium or serum-free medium for different time 
points. In another variant, 90% confluent HUVEC cells were washed once as above and 
stimulated for 20 hours with different concentrations of LPS or IFN-γ in complete medium or 
stimulated with 40 ng/mL (0.1μM) dexamethasone in complete medium for different time 
points. After the stimulations, the cells were subjected to the protein expression analysis by 
western blot, as described further on.  
2.4. Protein expression analysis – western blot (WB) 
Cells were washed twice with ice-cold DPBS, then lysed on ice with RIPA buffer 
(50 mM Tris-HCl, 150 mM NaCl, pH.8.0, 0.1% SDS, Triton X-100, 0.5% deoxycholate) 
supplemented with HALT protease phosphatase inhibitors (#1861281) from Thermo 
Scientific and 2mM sodium orthovanadate (#450243) from SIGMA. A cell scraper was used 
in order to detach cells from plate and lysates were transferred to pre-chilled eppendorf tubes. 
After 10 to 15 minutes incubation on ice, lysates were centrifuged 10 000 rpm 1 min at +4°C 
to remove cell residues and nuclei. The protein content in the cell lysates was measured with 
Pierce BCA Protein Assay Kit (#23227) from Thermo Scientific. Cell lysates (10 μg or 5 μg 
of total protein) was separated on 4-15% SDS-PAGE gels (Bio Rad,) under reducing 
conditions and blotted (Bio Rad Trans-Blot Turbo Transfer Starter System) onto PVDF 
membranes (Bio Rad). Membranes were blocked in blocking buffer; 3% fish gelatin from 
Nordland (#9000-79-8) diluted in immunowash (50 mM Tris HCl, 0.15M NaCl, 0.01% 
Tween-20, pH.8.0.). Next, probed for 1h at room temperature (RT) or over night at +4C with 
primary antibodies in the blocking buffer. Membranes were washed with the immunowash 
and probed with HRP-conjugated secondary antibodies for 1h at RT. The blots were 
visualized with Bio Rad Molecular Imager Gel Doc XR+ system. Prior the visualization 
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the membranes were incubated for 1 minute with the Chemiluminescent HRP Substrate 
(#WBKLS0500) from Millipore.  Western blot analysis and quantification was done with the 
use of the Bio Rad ImageLab 4.0.1 program. Note that all western blot results are presented as 
normalized against loading control. Membranes were stripped with 0.4 M NaOH and 
re-probed after a washing and blocking step as above. 
2.5. Immunoprecipitation (IP) 
HUVECs were grown until 90% confluence. Cells were washed once with DPBS and 
incubated for 2 hours in serum-free medium, followed by 15 minutes stimulation with the 
appropriate concentrations of either anti-Axl (AF154) or Gas6. After that, lysates and protein 
concentration was obtained with the same procedure as for the WB. Equal lysates amounts 
(at least 150 μg) were suspended in RIPA- lysis buffer supplemented with protease and 
phosphatase inhibitors as above. Next, rec-Protein G-Sepharose 4B conjugate beads  
(#101242) from Invitrogen, were added together with 40 μg of anti-Axl 042 (home made) or 
with 2 μg of anti-Axl (AF154). Cell lysates were incubated for at least 1.5 hours at +4°C with 
rotation. Immunoprecipitates were pelleted for 5 min with 1000g at +4°C, washed once with 
phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 1.8 mM 
KH2PO4, pH. 7.4) and pelleted again.  Lysates were separated on 4-15% SDS-PAGE gels 
under reducing conditions, followed by transfer onto PVDF membranes. The membranes 
were blocked in 3% fish gelatin in immunowash and first probed with anti- p-Tyr (Santa 
Cruz), then with anti-Axl H-124 or anti-Axl C-20 (Santa Cruz). The western blots were 
developed and analyzed as above. 
2.6. Fluorescence-activated cell sorting (FACS) 
Cells were rinsed once with DPBS and trypsinized with 200μl (6-well plate) or 100μl 
(12-well plate) of TrypLE Express (GIBCO), then transferred to pointy bottom mictrotiter 
plates (NUNC) and centrifuged at 700g for 3 minutes at +4°C.  Supernatant was removed and 
the cells were re-suspended in 150μl full medium, centrifuged as above.  Next, the cells were 
washed with 1% BSA in PBS, then stained with antibodies against VCAM-1, ICAM-1 or 
E-selectin (R&D) diluted in 1% BSA in PBS. After 1h incubation (on ice, under tin foil), the 
cells were pelleted as above and re-suspended in 100μl of 1% BSA in PBS. Cell suspension 
was transferred to FACS tubes containing 1 ml of the 1%BSA in PBS and FACS analysis was 
performed on the Partec Cyflow Space flow cytometer with the use of FlowMAX 2.5 
program. The cells were gated, based on forward scatter (FCS) and side scatter 
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(SCC).  ICAM-FITC and E-selecting FITC signals were monitored by measuring the 
geometrical mean fluorescence on channel FL1 (green), whereas VCAM-APC was measured 
on FL6 (red). At least 5000 cells per sample were counted. Data analysis was performed with 
the use of the FlowJo 8.8.7 program. 
2.7. Enzyme-linked immunosorbent assay (ELISA) for cytokines 
After various stimulation, cell supernatants were collected and stored at -20°C.  Before use, 
supernatants were centrifuged 10 000 rpm for 5 minutes and transferred to fresh tubes. 
ELISAs were performed according to the manual provided by the R&D Systems: IL-6 
(#DY206), GM-CSF (DY215) and CCL2/MCP-1 (#DY279). 
2.8. Statistics 
Statistical analysis was performed in the GraphPad Prism Version 6.0e. One-way ANOVA 
with Dunnet’s multiple comparison test was used to analyze the statistical significance of 
differences between the groups. P-values below 0.05 were considered to be significant. 
Experiments were carried out on at least three different occasions unless specified differently 
in the figure legend. 
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3. RESULTS 
In order to elucidate the role of TAM receptors in the endothelial inflammatory response, 
many different approaches have been considered. Here, some of them are presented, showing 
the complexity and multifunctionality of these receptors. It is worth stressing that our 
observations are based on Axl and Mer receptor activity, as we were unable to detect the 
expression of Tyro3 in human umbilical vein endothelial cells (HUVEC) (data not shown). 
3.1. Axl promotes TNF-α-mediated endothelial inflammation 
It has been shown that Axl and Gas6 knockdown in human primary endothelial cells causes 
a significant reduction of ICAM-1 expression, in response to TNF- α stimulation (65). In 
order to validate this finding, we performed a similar experiment investigating both the 
expression of adhesion molecules as well as secretion of inflammatory cytokines in response 
to TNF- α in TAM-deficient and TAM-sufficient cells. HUVECs treated with siRNA against 
the different TAM-receptors were stimulated for 20h with TNF- α as presented in Figure 4. 
 
We confirmed the effectiveness of the TAM knockdown by western blot (Figure 5, A). We 
observed a significant reduction in the expression of ICAM-1 and VCAM-1 in response to 
TNF-α, in Gas6 deficient cells compared to control cells. Furthermore, Axl deficiency 
resulted in a significant reduction of TNF-α -induced VCAM-1 expression. We did not see 
any significant changes in the expression of adhesion molecules upon Mer or Tyro3 siRNA 
knock down. In addition, TAM knock-down did not affect the basal expression of ICAM-1, 
Figure 4 Experiment overview. HUVEC cells were first treated with siRNA against different TAM
receptors or Gas6 in serum-free conditions. After 4 hours treatment, serum was added and the
incubation continued until next day. Then, the medium was changed, and after 7 hours of recovery
the cells were stimulated with 10 ng/mL TNF-α in serum-free medium for 20 hours. After that, FACS
analysis for the expression of adhesion molecules on the cell surface, and ELISA analysis for
secretion of the inflammatory cytokines were performed. 
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VCAM-1 or E-selectin in the absence of TNF-α stimulation (Figure 5, B). Next, we evaluated 
the secretion of IL-6, MCP-1 or GM-CSF into the cell culture supernatants upon TNF-α 
stimulation (Figure 5, C).  We observed a significantly lower secretion of IL-6 and MCP-1 by 
Axl deficient cells compared to control cells upon TNF- α exposure. In contrast, GM-CSF 
secretion in response to TNF- α was enhanced in Mer deficient cells.  
  20
3.2. Effects of TAMs during chronic inflammation 
To investigate the role of TAMs on adhesion molecule expression and cytokine secretion in 
a more chronic inflammatory setting we set up an experiment as presented in the Figure 6. In 
this model, prior to the siRNA knock-down, we treated HUVEC cells for two days with 
TNF-α in complete medium. After that, we performed TAM siRNA knock-down, followed by 
additional stimulation with TNF- α in starvation medium for 24 hours. As readout, we 
monitored adhesion molecule expression by FACS and cytokine secretion by ELISA.  
 First, we evaluated the efficiency of siRNA knock-down by western blot (Figure 7, A). We 
observed that Mer knock-down was not as efficient as that of Axl in these experiments. Next, 
we measured the expression of ICAM-1, VCAM-1 and E-selectin in TAM-deficient cells in 
response to TNF- α stimulation (Figure 7, B). We observed that Mer knock-down leads to 
a slight decrease in the expression of VCAM-1 and a significant increase in the expression of 
E-selectin, as compared to control cells. In contrast, Axl deficiency caused a significant 
decrease in the expression of E-selectin.  Notably, TAM knock-down did not affect the basal 
Figure 5 Axl promotes TNF-α mediated endothelial inflammation. (A) Western blot analysis for
TAM knockdown efficiency. After siRNA treatment, cell lysates were prepared and blotting procedure
was performed as described in the Materials and Methods. Membranes were first probed for either
Axl or Mer, then re-probed for β-actin as a loading control, as presented on the left part of the panel
A. Blot calculations (n=3) are presented on the right side of the panel A. (B) FACS analysis for the
E-selectin, ICAM-1, VCAM-1 expression. FACS histograms (upper part of the panel B) as well as
quantification of expression (n=3), normalized against the control siRNA, TNF-α stimulated sample,
are presented in the lower part of the panel B. Please note that “no stimulation” refers to the control
sample, which was incubated in full medium, “no siRNA” means that the sample was treated the
same way as the stimulated variants, only with no siRNA added. (C) ELISA analysis for cytokine
secretion (n=2). Note that raw absorbance values were plotted, due to the high signals, exceeding the
standard curve.  *P <0.05, **P <0.01, ***P <0.001, ****P<0.0001 (One-way ANOVA with Dunnet’s
multiple comparison test), ns-not significant. 
 
Figure 6 Experiment overview. HUVEC cells were pre-stimulated for 48 hours with 10 ng/mL TNF-α
in complete medium, followed by treatment with anti-TAM siRNA in serum-free medium. After 4
hours, serum was added and the cells were allowed to recover over night. Cells were then stimulated
with 10 ng/mL TNF-α in starvation medium and incubated for 24 hours. After that, the analysis for
adhesion molecule expression by FACS, were carried out. Prior to the FACS analysis, supernatants
were collected and subjected to the ELISA analysis, in order to check for secretion of the
inflammatory cytokines. 
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expression of ICAM-1, VCAM-1 or E-selectin in the absence of TNF- α stimulation. Further, 
we investigated the secretion of inflammatory cytokines by performing ELISA on 
supernatants collected after the treatment (Figure 7,C). We observed a tendency of increased 
GM-CSF secretion when Mer was knocked down and reduced secretion when Axl was 
knocked down, but this did not reach statistical significance. In order to study whether the 
initial 48-h TNF- α stimulation altered Mer or Axl expression in the cells, we studied Axl/Mer 
expression changes by western blot (Figure 7,D). No significant changes in either Mer or Axl 
expression levels were observed. 
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3.3. Anti-Axl antibody activates the receptor 
In order to test the effect of different external TAM-blocking agents, we treated HUVEC cells 
with TAM antibodies simultaneously to TNF- α stimulation, and monitored the expression of 
adhesion molecules. We observed no differences in expression of ICAM-1, VCAM-1 and 
E-selectin between cells treated with TAM-antibodies together with TNF- α and cells treated 
with TNF-α alone (Figure 8, A). A study by Zagorska et al. (56) suggests that polyclonal 
TAM-reactive antibodies mediated TAM-activation in mouse bone marrow-derived 
macrophages.  To investigate whether our antibodies stimulated TAM-activation in HUVEC 
cells, we performed Axl immunoprecipitation from cells stimulated with either Gas6 or the 
same anti-Axl antibodies used in the blocking experiment (R&D Systems). The 
immunoprecipitated Axl was clearly tyrosine phosphorylated, indicating Axl activation, in 
both anti-Axl and Gas6 stimulated cells (Figure 8, B). This shows that the antibody treatment, 
at least in the case of Axl, actually activated the receptor as opposed to blocking it, which 
might explain the discrepancies in the regulation of adhesion molecule expression compared 
to Axl siRNA treated cells. 
  
Figure 7 Effects of TAMs during chronic inflammation. (A) The TAM knock-down efficiency was
confirmed by western blot. After 96 hours, cell lysates were prepared and subjected to Axl or Mer
expression analysis, with β-actin serving as a loading control; blot calculations (n=3) are presented on
the right site of the panel A. (B) FACS analysis for adhesion molecule expression upon TNF-α
stimulation. Histograms are presented in the upper part with corresponding expression quantifications
(n=4), normalized against the control siRNA (siControl), TNF- α stimulated sample, placed underneath.
Note that “no stimulation” refers to the sample incubated in full medium throughout the experiment. (C)
ELISA analysis for the secretion of inflammatory cytokines. After 96 hours, cell supernatants were
collected and analyzed with commercially available ELISA kits. (D) Axl/Mer expression analysis in
HUVEC cells in response to TNF- α stimulation in full medium. After various time points, cell lysates
were prepared and subjected to protein expression analysis by western blot, and probed first for Axl or
Mer, then for β-actin as a loading control. Blot calculation (n=2) is presented in the lower part of the
panel. *P <0.05, **P <0.01 (One-way ANOVA with Dunnet’s multiple comparison test), ns-not
significant. 
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Figure 8 Anti-Axl antibody activates the receptor. (A) FACS analysis for adhesion molecule
expression in HUVEC cells stimulated for 20 hours with 5μg/mL anti-Axl (AF154) (α-Axl),
anti-Mer  (AF891) (α-Mer) or anti-Tyro3 (AF859) (α-Tyro3) together with 10ng/mL TNF- α, or TNF- α
alone, in serum-free medium. Histograms are presented in the upper panel A; note that  “control, no
stain” refers to a not stimulated, full medium incubated sample, where no antibody against adhesion
molecules was added, unlike “stained”, where this antibody was added. Lower panel A, represents
adhesion molecules expression quantification (n=3), normalized against the TNF- α stimulated
sample. (B) Axl immunoprecipitation from the anti-Axl  (AF154) or Gas6 stimulated HUVEC cells.
Cells were treated with either anti-Axl or Gas6 in serum free medium for 15 minutes. Lysates were
prepared and blotting was performed as described in the Materials and Methods. Blots were probed
first for p-Tyr, then for total Axl as a loading control. 
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3.4. Cell secreted protein S inhibits adhesion molecules 
expression 
In order to study the role of TAM ligands in the endothelial inflammation, we stimulated 
HUVEC cells with TNF- α together with ligand or anti-ligand antibody for 20 hours in 
serum-free medium. This gave us an opportunity to monitor the contribution of exogenously 
added or endogenously produced ligand to the endothelial inflammatory response. First, we 
confirmed the activation of Axl receptor by Gas6 in HUVEC cells with Axl 
immunoprecipitation, and we observed a strong signal from tyrosine phosphorylation already 
after stimulating with 200 ng/ml of Gas6 (Figure 9, A). Next, we performed FACS analysis 
for adhesion molecule expression. We did not observe any effect on adhesion molecule 
expression, when stimulating HUVECs with anti-Gas6 antibody (α-Gas6) together with 
TNF- α as opposed to TNF- α alone, however the treatment with exogenous Gas6 caused 
a significant reduction of TNF- α -induced E-selectin (Figure 9, panel B). We performed the 
same analysis for proteins S and in this case, stimulation with exogenous protein S together 
with TNF- α did not cause any significant changes in the expression of adhesion molecules. 
However anti-protein S antibody (α-protein S) treatment led to a significant increase in 
TNF-α mediated expression of ICAM-1, VCAM-1 and E-selecting, by around 50% 
(Figure 9, panel C). 
  
  26
 
  
Figure 9 Cell secreted protein S inhibits adhesion molecule expression. (A) Axl activation in
HUVECs pre-starved for 2 hours and then left unstimulated (control) or stimulated for 15 minutes with
Gas6 in serum-free medium. Blots were first probed for p-Tyr to look for the receptor activation, then
for total Axl as a loading control. (B) FACS analysis of adhesion molecules expression in HUVECs,
pre-starved for 2 hours, then stimulated for 20 hours with 10 ng/mL TNF- α alone or with, either
200 ng/mL Gas6 or 2.5 μg/mL anti-Gas6 (α-Gas6) in starvation medium or starvation medium alone
(control), n=3. (C) Adhesion molecule expression in HUVECs, pre-starved for 2 hours, then
stimulated for 20 hours with 10 ng/mL TNF-α alone or with, either 5 μg/mL protein S or
50 μg/mL anti-protein S (α-protein S) in starvation medium or starvation medium alone (control), n=3.
*P <0.05 (One-way ANOVA with Dunnet’s multiple comparison test), ns-not significant. 
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3.5. Mer receptor expression is upregulated by starvation  
It has been shown that upregulation of TAM receptor expression can be triggered by different 
agents, both pro and anti-inflammatory. We decided to test some of these stimuli in human 
endothelial primary cells, as most of the studies have been carried out in immune cells. First, 
we tested whether TNF- α in serum-free medium would affect Axl/Mer expression in 
HUVEC cells, as we could previously observe a strong inflammatory response upon this 
stimulation. We treated the cells with either serum-free medium alone or starvation medium 
supplemented with TNF- α, for 24 or 48 hours (Figure 10, A). We observed a strong 
down-regulation of Axl expression upon the TNF- α treatment; however further repetitions 
did not prove it as a pattern. On the other hand, Mer expression was not affected by TNF- α 
stimulation, nevertheless starvation potently upregulated this receptor. According to the study 
of Zagorska et al. (56), Axl expression is upregulated by inflammatory stimuli such as 
lipopolysaccharide (LPS) and interferon- γ (IFN- γ) in mouse bone marrow-derived 
macrophages. We performed similar analysis in HUVEC cells, stimulating with different 
concentrations of either LPS or IFN- γ for 20 hours in complete medium followed by western 
blot analysis (Figure 10, B). As a result, we did not see any significant changes in the 
expression pattern of either Axl or Mer, only slightly elevated levels of Axl upon the 
stimulation with high concentrations of IFN- γ. Further, we decided to investigate Axl and 
Mer expression in endothelial cells upon the stimulation with the immunosuppressive 
glucocorticoid dexamethasone (Dex), as it was reported to be a potent upregulating agent for 
Mer expression in human monocyte-derived macrophages (80) as well as in mouse bone 
marrow-derived macrophages (56) (Figure 10 ,C). We stimulated HUVECs with 40 ng/mL 
Dex in complete medium for different time points followed by western blot analysis. Dex 
stimulation did neither affect the expression of Mer nor Axl. 
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Figure 10 Starvation upregulates Mer expression. (A) Axl/Mer expression upon stimulation with
10 ng/mL TNF- α in serum-free medium or starvation medium alone in HUVEC cells. After 24 and 48
hours lysates were prepared and analyzed by western blot for Axl and Mer expression. The blot
quantification (n=2) is presented in the lower part of the panel. Note that “control” corresponds to a
sample incubated in complete medium throughout the experiment. (B) Immunoblot analysis of Axl
and Mer upon 20 hours stimulation in complete medium with inflammatory agents - LPS and IFN-γ.
Blot quantification (n=2) is presented underneath with “control” referring to the sample incubated in
full medium. (C) Immunoblot analysis of Axl and Mer expression after stimulating for different time
points with the immunosuppressive agent dexamethasone (Dex) in complete medium. Again,
“control” refers to the complete-medium incubated sample. Note that in the presented results β-actin
serves as a loading control. 
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4. DISCUSSION 
TAM receptors are ubiquitously present in the human body, which determines their 
differentiated role in many processes. Their significance in restoring homeostasis has been 
extensively studied. Moreover, TAM RTKs play an important role in the vasculature, by 
affecting angiogenesis and promoting cell survival. Notably, they have been reported to 
modulate human endothelial inflammation, but with conflicting results provided in different 
studies (65, 66). In this project, we decided to further investigate the role of TAMs in 
inflammatory signaling in primary human endothelial cells, hence contributing to better 
understanding of these kinases in the inflammatory response. 
4.1. Axl/Gas6 signaling plays a pro-inflammatory role in 
endothelial inflammation 
We studied the role of Axl and Mer in the inflammatory signaling in HUVEC cells, by 
measuring adhesion molecule expression and inflammatory cytokine secretion. We developed 
two experimental models, which enabled us to monitor TAM response in the acute (Figure 4) 
and chronic (Figure 6) inflammatory environments. We found that Axl and Gas6 signaling 
exhibits pro-inflammatory properties, as their knock-down efficiently reduced the expression 
of adhesion molecules and secretion of inflammatory cytokines in HUVEC cells, in response 
to TNF-α-mediated inflammation.  This conclusion is in agreement with Tjwa et al. (65). On 
the other hand, we observed that Mer knock-down leads to the increased expression of both 
adhesion molecules and inflammatory cytokines, thereby suggesting anti-inflammatory 
properties. It is worth noticing that conclusions regarding adhesion molecules in the acute 
variant are based on the observations for ICAM-1 and VCAM-1 expression, since we did not 
obtain any significant results for E-selectin. This might be due to the fact that E-selectin 
expression peak has been shown to be around 4-6 hours after the acute cytokine stimulation, 
whereas ICAM-1 and VCAM-1 effect persists for around 72 hours (81). This indicates that 
E-selectin might play a bigger role after stimulating with TNF-α for 6 hours instead of 20, 
which is one of our future plans. We did, however, observe significant values for the 
regulation of  E-selectin expression by TAMs in the chronic stimulation variant (Figure 7, B). 
This might be difficult to explain, as there are many limitations regarding this model, which 
will be discussed later on. Further, we noticed discrepancies in the ELISA results between 
acute (Figure 5, C) and chronic (Figure 7, C) models.  We hypothesize that low expression 
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level of IL-6 and MCP-1 in the chronic variant compared to the acute model, might be the 
result of negative feedback loop regulating cytokine expression. Cells, after being exposed to 
a chronic inflammatory condition, switch on various cell rescue programs, and one of them 
might be the down-regulation of expression of these inflammatory agents. We could see, 
however, a similar pattern of GM-CSF secretion in both models. This might be due to the fact 
that GM-CSF, which serves as a leukocyte growth factor (82), might be differentially 
regulated than IL-6 and MCP-1. It is worth stressing, that there are many limitations 
regarding the chronic inflammatory model, as to the effect of pre-stimulation step. 
We managed to examine the Axl/Mer expression levels after the pre-stimulation step 
(Figure 7, D), and we concluded no changes. Nevertheless, we need more controls to validate 
this model. One of them is to investigate the effect of pre-stimulation on adhesion molecule 
expression after the siRNA knock-down, which is our future plan. Altogether, these 
experiments reveal the heterogeneity of Axl/Mer function in endothelial inflammation. 
Interestingly, Zagorska et al. have reported similar conclusion (56), based on studies in mouse 
bone marrow-derived immune cells.  In addition, Gas6 has been reported as an indicator of 
inflammation, as increased amounts of this protein in plasma are observed in septic patients 
(83, 84). Based on our and Tjwa et al. (65) observations, it is possible that increased 
circulating Gas6 promote endothelial inflammation in sepsis. These conclusions are 
suggesting Gas6 as a possible target for the treatment of sepsis and transplantation-induced 
organ rejection (65). Nevertheless, it is worth keeping in mind that Gas6 has been reported to 
have an immunosuppressive role in immune response in macrophages and dendritic cells 
(Figure 2), which could be affected by this treatment. It is also worth stressing that 
pro-inflammatory properties are essential for the activation of the immune response and 
extravasation of immune cells from the vasculature into the tissues, which is important to 
consider when suggesting therapeutic applications. Conversely, decreased Gas6 plasma 
concentrations have been detected in patients with type 2 diabetes, associating with adiposity, 
insulin resistance, altered glucose tolerance and inflammation (85). The role of circulating 
Gas6 in contrast to Gas6 produced locally by cells in the immediate vicinity on the regulation 
of vascular responses remains to be elucidated. 
4.2. Axl receptor is ligand-independently activated by anti-Axl 
antibody 
To date, TAM agonists, that would exhibit absolute receptor specificity in human tissues, 
have not been found. In the work of Zagorska et al., however, the authors described that 
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anti-TAM antibodies act as TAM-activating agents in mouse bone marrow-derived 
macrophages. Our study suggests that affinity purified polyclonal anti-Axl antibody (R&D 
Systems) potently activates the receptor instead of blocking it (Figure 8, B). This finding 
indicates a possibility of selective activation of endothelial expressed Axl regardless of ligand 
binding. This observation led us to think of possible use of Axl-activating antibodies as 
therapeutics, since Axl/Gas6 signaling has been shown to have a pro-survival function in 
endothelium, by acting as an anti-apoptotic agent (75). Notably, increased apoptosis is 
associated with many cardiovascular complications, such as atherosclerosis and pulmonary 
hypertension (86-88). Nevertheless, it is worth keeping in mind that the activation of Axl 
receptor might be not tissue specific, and with respect to the various functions of Axl, should 
be examined for side effects. Further, we did not confirm the activation of Mer receptor by 
anti-Mer antibody, as we currently working on the protocol for efficient immunoprecipitation 
of Mer receptor. However, based on our observations, we concluded that anti-Mer antibody 
(R&D Systems) lacks the specificity for endothelial expressed Mer (data not shown). This 
explains, why we did not observe any effect on adhesion molecule expression when blocking 
Mer with this antibody (Figure 8, A). We reasoned that TAM receptors are differently 
glycosylated, depending on a tissue as well as cell’s growth phase. If the antibody is directed 
against the site of glycosylation, it might lose its specificity. This could be of use if one aims 
to produce tissue-specific TAM-activating antibodies.  
4.3. Mer/protein S axis has an anti-inflammatory function in 
endothelial inflammation 
We sought to elucidate the role of TAM receptor ligands- Gas6 and protein S in the 
endothelial inflammation. We found that the addition of exogenous ligand does not affect 
TAM response to inflammatory stimuli, regarding the adhesion molecule 
expression (Figure 9). We hypothesize that endothelial cells produce sufficient amounts of 
ligands to trigger TAM-activation, hence adding extra does not change their response. 
Notably, blocking endogenous Gas6 with anti-Gas6 antibody did not show any effect 
(Figure 9), when compared to siRNA knock-down experiment, where we concluded pro-
inflammatory tendencies of Gas6 (Figure 5). These findings are contradictory to the work of 
Avanzi et al.(66), where the authors claimed anti-inflammatory properties of endogenously 
produced Gas6 in endothelium. However, it is worth stressing that according to their 
proposal, pro-inflammatory triggers would diminish Gas6 concentration in endothelium, 
which would consequently lead to the activation of the proadhesive machinery.  
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In our study, however, we did not validate this finding and therefore it might be that the 
TNF- α stimulation on its own blocks Gas6 secretion from the cells. Another issue to consider 
is the specificity of the anti-Gas6 antibody, with respect to the possible modifications of Gas6 
produced by HUVEC cells. Again, if this antibody is directed to the site of modification, it 
might lose its Gas6-targeting function. Further, we blocked the exogenously secreted protein 
S with anti-protein S antibody and we observed a significant increase in the expression of 
adhesion molecules (Figure 9, C). This indicates the anti-inflammatory properties of 
endothelial cell secreted protein S. To date, protein S is known to be a potent ligand for Mer 
receptor (21), and as we previously described, Mer deficiency leads to the elevated expression 
of inflammatory cytokines and adhesion molecules. These observations allow us to speculate 
the existence of Mer/protein S-mediated anti-inflammatory signaling in endothelium. 
Notably, the role of Mer in suppressing inflammation has been already confirmed in mouse 
immune cells (44, 51). 
4.4. Starvation upregulates Mer expression in endothelium 
We decided to test whether stimulation with different agents would affect Axl and Mer 
expression in HUVEC cells. We found that Axl expression is reduced upon the TNF-α 
stimulation in serum-free medium, however further repetitions did not confirm this finding. In 
addition, Mer expression was strongly upregulated upon starvation (Figure 10, A). Notably, 
the same stimulation was performed in complete-medium conditions, showing no effect on 
Axl and Mer expression (Figure 7, D). This observations allow us to hypothesize that 
endothelium promotes the expression of Mer as a response to stress conditions such as 
starvation. This might be one of the cellular rescue mechanisms, as we previously presented 
the anti-inflammatory properties of Mer-mediated signaling. Another reason could be the 
significant role of Mer in phagocytosis of apoptotic cells (29, 53). The cells in the starvation 
environment might “prepare” for apoptosis by expressing more Mer, which could then 
promote an efficient clearance of dying cells upon extended starvation. Further, in order to 
explain discrepancies between the experiments, we decided to measure mRNA levels of Mer 
and Axl with quantitative RT-PCR (qRT-PCR). Nevertheless, we did not obtain any reliable 
results due to the very low signals of Axl and Mer expression (data not shown). In order to 
test this methods in the future, we will need to optimize the reaction conditions. In addition, 
we stimulated HUVECs with various agents, which were described to potently induce Axl 
and Mer expression in immune cells. We found that these stimuli did not cause any response 
with respect to Axl and Mer expression in endothelial cells (Figure 10). As a result of this 
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approach, we concluded that depending on the cell type, different agents affect TAM 
expression. This might be due to the distinct roles of TAM receptors in different cells, thus 
the pathways leading to their activation might be also diverse. 
4.5. Future plans 
First of all, we would like to develop an efficient method for immunoprecipitation (IP) of Mer 
in primary human endothelial cells. Moreover, we plan to confirm the specificity of Axl 
activation by anti-Axl antibody by stimulating HUVECs with anti-Axl and performing an IP 
analysis for Mer receptor activation. Subsequently, we will test the properties of anti-Mer 
antibodies to selectively activate Mer in endothelial cells. Furthermore, we would like to 
investigate TAM expression levels upon the stimulation with different inflammatory agents 
such as Interleukin-1 beta (IL-1). In addition, we would like to test whether TAMs regulate 
IL-1-mediated adhesion molecule expression and cytokine secretion, compared to 
TNF-α-mediated effects. Importantly, we will optimize qRT-PCR conditions and measure 
Axl and Mer expression in response to the treatment with various stimuli. This will 
complement protein expression analysis by western blot. In addition, we would like to test 
whether TNF- stimulation affects the Gas6 secretion by HUVEC cells, as proposed in the 
Avanzi et al. (66). Finally, we plan to verify our observations in other primary human 
endothelial cell line such as human aortic endothelial cells (HAEC). 
4.6. Final conclusions 
Our study provides an important contribution to better understanding of the role of TAM 
receptors in endothelial inflammation, since conflicting conclusions have been reported (65, 
66). We presented a pro-inflammatory role of Axl/Gas6 axis, which is in line with Tjwa.et al. 
(65), and anti-inflammatory properties of Mer/protein S signaling in primary human 
endothelial cells. We managed to prove ligand-independent activation of Axl by anti-Axl 
antibody (R&D Systems). Notably, we demonstrated that Mer receptor expression is potently 
elevated upon starvation as well as Axl and Mer upregulation by different agents is dependent 
on the cell type. Altogether, we presented diversification and complexity of Axl and Mer 
receptors functions in endothelial inflammation, hence suggesting the need for further 
research. 
  
  34
5. REFERENCES 
1.	 Rothlin	CV,	Ghosh	S,	Zuniga	EI,	Oldstone	MB,	Lemke	G.	TAM	receptors	are	pleiotropic	inhibitors	of	
the	innate	immune	response.	Cell.	2007;131(6):1124‐36.	
2.	 Borden	EC,	Sen	GC,	Uze	G,	Silverman	RH,	Ransohoff	RM,	Foster	GR,	et	al.	 Interferons	at	age	50:	
past,	current	and	future	impact	on	biomedicine.	Nature	reviews	Drug	discovery.	2007;6(12):975‐90.	
3.	 van	 der	 Meer	 JH,	 van	 der	 Poll	 T,	 van	 't	 Veer	 C.	 TAM	 receptors,	 Gas6,	 and	 protein	 S:	 roles	 in	
inflammation	and	hemostasis.	Blood.	2014;123(16):2460‐9.	
4.	 Sumpio	 BE,	 Riley	 JT,	 Dardik	 A.	 Cells	 in	 focus:	 endothelial	 cell.	 The	 international	 journal	 of	
biochemistry	&	cell	biology.	2002;34(12):1508‐12.	
5.	 Eckhart	W,	Hutchinson	MA,	Hunter	T.	An	activity	phosphorylating	tyrosine	in	polyoma	T	antigen	
immunoprecipitates.	Cell.	1979;18(4):925‐33.	
6.	 Lai	C,	Lemke	G.	An	extended	 family	of	protein‐tyrosine	kinase	genes	differentially	expressed	 in	
the	vertebrate	nervous	system.	Neuron.	1991;6(5):691‐704.	
7.	 Crosier	KE,	Hall	LR,	Lewis	PM,	Morris	CM,	Wood	CR,	Morris	JC,	et	al.	Isolation	and	characterization	
of	the	human	DTK	receptor	tyrosine	kinase.	Growth	factors.	1994;11(2):137‐44.	
8.	 O'Bryan	JP,	Frye	RA,	Cogswell	PC,	Neubauer	A,	Kitch	B,	Prokop	C,	et	al.	axl,	a	transforming	gene	
isolated	from	primary	human	myeloid	leukemia	cells,	encodes	a	novel	receptor	tyrosine	kinase.	Molecular	
and	cellular	biology.	1991;11(10):5016‐31.	
9.	 Graham	 DK,	 Dawson	 TL,	 Mullaney	 DL,	 Snodgrass	 HR,	 Earp	 HS.	 Cloning	 and	mRNA	 expression	
analysis	 of	 a	 novel	 human	 protooncogene,	 c‐mer.	 Cell	 growth	&	 differentiation	 :	 the	molecular	 biology	
journal	of	the	American	Association	for	Cancer	Research.	1994;5(6):647‐57.	
10.	 Janssen	 JW,	 Schulz	 AS,	 Steenvoorden	 AC,	 Schmidberger	 M,	 Strehl	 S,	 Ambros	 PF,	 et	 al.	 A	 novel	
putative	tyrosine	kinase	receptor	with	oncogenic	potential.	Oncogene.	1991;6(11):2113‐20.	
11.	 Rescigno	J,	Mansukhani	A,	Basilico	C.	A	putative	receptor	tyrosine	kinase	with	unique	structural	
topology.	Oncogene.	1991;6(10):1909‐13.	
12.	 Sasaki	T,	Knyazev	PG,	Clout	NJ,	Cheburkin	Y,	Gohring	W,	Ullrich	A,	et	al.	Structural	basis	for	Gas6‐
Axl	signalling.	The	EMBO	journal.	2006;25(1):80‐7.	
13.	 Hafizi	 S,	 Dahlback	 B.	 Gas6	 and	 protein	 S.	 Vitamin	 K‐dependent	 ligands	 for	 the	 Axl	 receptor	
tyrosine	kinase	subfamily.	The	FEBS	journal.	2006;273(23):5231‐44.	
14.	 Mark	MR,	Scadden	DT,	Wang	Z,	Gu	Q,	Goddard	A,	Godowski	PJ.	rse,	a	novel	receptor‐type	tyrosine	
kinase	 with	 homology	 to	 Axl/Ufo,	 is	 expressed	 at	 high	 levels	 in	 the	 brain.	 The	 Journal	 of	 biological	
chemistry.	1994;269(14):10720‐8.	
15.	 Dai	 W,	 Pan	 H,	 Hassanain	 H,	 Gupta	 SL,	 Murphy	 MJ,	 Jr.	 Molecular	 cloning	 of	 a	 novel	 receptor	
tyrosine	kinase,	tif,	highly	expressed	in	human	ovary	and	testis.	Oncogene.	1994;9(3):975‐9.	
16.	 Seitz	HM,	Camenisch	TD,	Lemke	G,	Earp	HS,	Matsushima	GK.	Macrophages	and	dendritic	cells	use	
different	 Axl/Mertk/Tyro3	 receptors	 in	 clearance	 of	 apoptotic	 cells.	 Journal	 of	 immunology.	
2007;178(9):5635‐42.	
17.	 O'Donnell	K,	Harkes	IC,	Dougherty	L,	Wicks	IP.	Expression	of	receptor	tyrosine	kinase	Axl	and	its	
ligand	Gas6	in	rheumatoid	arthritis:	evidence	for	a	novel	endothelial	cell	survival	pathway.	The	American	
journal	of	pathology.	1999;154(4):1171‐80.	
18.	 Wilhelm	I,	Nagyoszi	P,	Farkas	AE,	Couraud	PO,	Romero	IA,	Weksler	B,	et	al.	Hyperosmotic	stress	
induces	 Axl	 activation	 and	 cleavage	 in	 cerebral	 endothelial	 cells.	 Journal	 of	 neurochemistry.	
2008;107(1):116‐26.	
  35
19.	 Sather	S,	Kenyon	KD,	Lefkowitz	JB,	Liang	X,	Varnum	BC,	Henson	PM,	et	al.	A	soluble	form	of	the	
Mer	 receptor	 tyrosine	kinase	 inhibits	macrophage	clearance	of	 apoptotic	 cells	 and	platelet	 aggregation.	
Blood.	2007;109(3):1026‐33.	
20.	 Wu	J,	Ekman	C,	 Jonsen	A,	Sturfelt	G,	Bengtsson	AA,	Gottsater	A,	et	al.	 Increased	plasma	levels	of	
the	soluble	Mer	 tyrosine	kinase	receptor	 in	systemic	 lupus	erythematosus	relate	 to	disease	activity	and	
nephritis.	Arthritis	research	&	therapy.	2011;13(2):R62.	
21.	 Stitt	TN,	Conn	G,	Gore	M,	Lai	C,	Bruno	J,	Radziejewski	C,	et	al.	The	anticoagulation	factor	protein	S	
and	 its	 relative,	 Gas6,	 are	 ligands	 for	 the	 Tyro	 3/Axl	 family	 of	 receptor	 tyrosine	 kinases.	 Cell.	
1995;80(4):661‐70.	
22.	 Varnum	BC,	Young	C,	Elliott	G,	Garcia	A,	Bartley	TD,	Fridell	YW,	et	al.	Axl	receptor	tyrosine	kinase	
stimulated	 by	 the	 vitamin	 K‐dependent	 protein	 encoded	 by	 growth‐arrest‐specific	 gene	 6.	 Nature.	
1995;373(6515):623‐6.	
23.	 Caberoy	 NB,	 Zhou	 Y,	 Li	 W.	 Tubby	 and	 tubby‐like	 protein	 1	 are	 new	 MerTK	 ligands	 for	
phagocytosis.	The	EMBO	journal.	2010;29(23):3898‐910.	
24.	 Caberoy	NB,	Alvarado	G,	Li	W.	Tubby	regulates	microglial	phagocytosis	through	MerTK.	Journal	of	
neuroimmunology.	2012;252(1‐2):40‐8.	
25.	 Caberoy	NB,	Alvarado	G,	Bigcas	JL,	Li	W.	Galectin‐3	is	a	new	MerTK‐specific	eat‐me	signal.	Journal	
of	cellular	physiology.	2012;227(2):401‐7.	
26.	 Manfioletti	G,	Brancolini	C,	Avanzi	G,	Schneider	C.	The	protein	encoded	by	a	growth	arrest‐specific	
gene	 (gas6)	 is	 a	 new	 member	 of	 the	 vitamin	 K‐dependent	 proteins	 related	 to	 protein	 S,	 a	 negative	
coregulator	in	the	blood	coagulation	cascade.	Molecular	and	cellular	biology.	1993;13(8):4976‐85.	
27.	 Bandyopadhyay	 PK.	 Vitamin	 K‐dependent	 gamma‐glutamylcarboxylation:	 an	 ancient	
posttranslational	modification.	Vitamins	and	hormones.	2008;78:157‐84.	
28.	 Tsou	WI,	 Nguyen	 KQ,	 Calarese	 DA,	 Garforth	 SJ,	 Antes	 AL,	 Smirnov	 SV,	 et	 al.	 Receptor	 tyrosine	
kinases,	TYRO3,	AXL,	and	MER,	demonstrate	distinct	patterns	and	complex	regulation	of	 ligand‐induced	
activation.	The	Journal	of	biological	chemistry.	2014;289(37):25750‐63.	
29.	 Lemke	G,	Burstyn‐Cohen	T.	TAM	receptors	and	the	clearance	of	apoptotic	cells.	Annals	of	the	New	
York	Academy	of	Sciences.	2010;1209:23‐9.	
30.	 Lemke	 G,	 Rothlin	 CV.	 Immunobiology	 of	 the	 TAM	 receptors.	 Nature	 reviews	 Immunology.	
2008;8(5):327‐36.	
31.	 Nagata	K,	Ohashi	K,	Nakano	T,	Arita	H,	Zong	C,	Hanafusa	H,	et	al.	Identification	of	the	product	of	
growth	arrest‐specific	 gene	6	 as	a	 common	 ligand	 for	Axl,	 Sky,	 and	Mer	 receptor	 tyrosine	 kinases.	 The	
Journal	of	biological	chemistry.	1996;271(47):30022‐7.	
32.	 Laurance	 S,	 Lemarie	 CA,	 Blostein	 MD.	 Growth	 arrest‐specific	 gene	 6	 (gas6)	 and	 vascular	
hemostasis.	Advances	in	nutrition.	2012;3(2):196‐203.	
33.	 Balogh	 I,	 Hafizi	 S,	 Stenhoff	 J,	 Hansson	 K,	 Dahlback	 B.	 Analysis	 of	 Gas6	 in	 human	 platelets	 and	
plasma.	Arteriosclerosis,	thrombosis,	and	vascular	biology.	2005;25(6):1280‐6.	
34.	 Ekman	C,	Stenhoff	J,	Dahlback	B.	Gas6	is	complexed	to	the	soluble	tyrosine	kinase	receptor	Axl	in	
human	blood.	Journal	of	thrombosis	and	haemostasis	:	JTH.	2010;8(4):838‐44.	
35.	 Burstyn‐Cohen	 T,	 Heeb	 MJ,	 Lemke	 G.	 Lack	 of	 protein	 S	 in	 mice	 causes	 embryonic	 lethal	
coagulopathy	and	vascular	dysgenesis.	The	Journal	of	clinical	investigation.	2009;119(10):2942‐53.	
36.	 Heeb	MJ,	Rosing	 J,	Bakker	HM,	Fernandez	 JA,	Tans	G,	Griffin	 JH.	Protein	S	binds	 to	and	 inhibits	
factor	 Xa.	 Proceedings	 of	 the	 National	 Academy	 of	 Sciences	 of	 the	 United	 States	 of	 America.	
1994;91(7):2728‐32.	
37.	 Fernandez	 JA,	Heeb	MJ,	Xu	X,	Singh	 I,	Zlokovic	BV,	Griffin	 JH.	Species‐specific	anticoagulant	and	
mitogenic	activities	of	murine	protein	S.	Haematologica.	2009;94(12):1721‐31.	
38.	 Nyberg	 P,	 He	 X,	 Hardig	 Y,	 Dahlback	 B,	 Garcia	 de	 Frutos	 P.	 Stimulation	 of	 Sky	 tyrosine	
phosphorylation	 by	 bovine	 protein	 S‐‐domains	 involved	 in	 the	 receptor‐ligand	 interaction.	 European	
journal	of	biochemistry	/	FEBS.	1997;246(1):147‐54.	
  36
39.	 Evenas	P,	Garcia	De	Frutos	P,	Linse	S,	Dahlback	B.	Both	G‐type	domains	of	protein	S	are	required	
for	 the	 high‐affinity	 interaction	 with	 C4b‐binding	 protein.	 European	 journal	 of	 biochemistry	 /	 FEBS.	
1999;266(3):935‐42.	
40.	 Lu	Q,	Lemke	G.	Homeostatic	regulation	of	the	immune	system	by	receptor	tyrosine	kinases	of	the	
Tyro	3	family.	Science.	2001;293(5528):306‐11.	
41.	 Lu	Q,	 Gore	M,	 Zhang	Q,	 Camenisch	T,	 Boast	 S,	 Casagranda	F,	 et	 al.	 Tyro‐3	 family	 receptors	 are	
essential	regulators	of	mammalian	spermatogenesis.	Nature.	1999;398(6729):723‐8.	
42.	 Korshunov	VA,	Mohan	AM,	Georger	MA,	Berk	BC.	Axl,	a	receptor	tyrosine	kinase,	mediates	flow‐
induced	vascular	remodeling.	Circulation	research.	2006;98(11):1446‐52.	
43.	 Angelillo‐Scherrer	A,	de	Frutos	P,	Aparicio	C,	Melis	E,	Savi	P,	Lupu	F,	et	al.	Deficiency	or	inhibition	
of	 Gas6	 causes	 platelet	 dysfunction	 and	 protects	 mice	 against	 thrombosis.	 Nature	 medicine.	
2001;7(2):215‐21.	
44.	 Camenisch	TD,	Koller	BH,	Earp	HS,	Matsushima	GK.	A	novel	receptor	tyrosine	kinase,	Mer,	inhibits	
TNF‐alpha	 production	 and	 lipopolysaccharide‐induced	 endotoxic	 shock.	 Journal	 of	 immunology.	
1999;162(6):3498‐503.	
45.	 Iwasaki	 A,	 Medzhitov	 R.	 Toll‐like	 receptor	 control	 of	 the	 adaptive	 immune	 responses.	 Nature	
immunology.	2004;5(10):987‐95.	
46.	 Zhu	 J,	 Mohan	 C.	 Toll‐like	 receptor	 signaling	 pathways‐‐therapeutic	 opportunities.	 Mediators	 of	
inflammation.	2010;2010:781235.	
47.	 Slack	JL,	Schooley	K,	Bonnert	TP,	Mitcham	JL,	Qwarnstrom	EE,	Sims	JE,	et	al.	Identification	of	two	
major	 sites	 in	 the	 type	 I	 interleukin‐1	 receptor	 cytoplasmic	 region	 responsible	 for	 coupling	 to	 pro‐
inflammatory	signaling	pathways.	The	Journal	of	biological	chemistry.	2000;275(7):4670‐8.	
48.	 Beutler	 B.	 Inferences,	 questions	 and	 possibilities	 in	 Toll‐like	 receptor	 signalling.	 Nature.	
2004;430(6996):257‐63.	
49.	 Sharif	MN,	Sosic	D,	Rothlin	CV,	Kelly	E,	Lemke	G,	Olson	EN,	et	al.	Twist	mediates	suppression	of	
inflammation	by	type	I	IFNs	and	Axl.	The	Journal	of	experimental	medicine.	2006;203(8):1891‐901.	
50.	 Hanada	 T,	 Yoshida	 H,	 Kato	 S,	 Tanaka	 K,	 Masutani	 K,	 Tsukada	 J,	 et	 al.	 Suppressor	 of	 cytokine	
signaling‐1	 is	 essential	 for	 suppressing	 dendritic	 cell	 activation	 and	 systemic	 autoimmunity.	 Immunity.	
2003;19(3):437‐50.	
51.	 Sen	 P,	Wallet	MA,	 Yi	 Z,	 Huang	 Y,	 Henderson	M,	Mathews	 CE,	 et	 al.	 Apoptotic	 cells	 induce	Mer	
tyrosine	kinase‐dependent	blockade	of	NF‐kappaB	activation	 in	dendritic	cells.	Blood.	2007;109(2):653‐
60.	
52.	 Deng	T,	Zhang	Y,	Chen	Q,	Yan	K,	Han	D.	Toll‐like	receptor‐mediated	inhibition	of	Gas6	and	ProS	
expression	 facilitates	 inflammatory	 cytokine	 production	 in	 mouse	 macrophages.	 Immunology.	
2012;135(1):40‐50.	
53.	 Bosurgi	L,	Bernink	JH,	Delgado	Cuevas	V,	Gagliani	N,	Joannas	L,	Schmid	ET,	et	al.	Paradoxical	role	
of	the	proto‐oncogene	Axl	and	Mer	receptor	tyrosine	kinases	in	colon	cancer.	Proceedings	of	the	National	
Academy	of	Sciences	of	the	United	States	of	America.	2013;110(32):13091‐6.	
54.	 Morizono	K,	Xie	Y,	Olafsen	T,	Lee	B,	Dasgupta	A,	Wu	AM,	et	al.	The	soluble	serum	protein	Gas6	
bridges	 virion	 envelope	 phosphatidylserine	 to	 the	 TAM	 receptor	 tyrosine	 kinase	 Axl	 to	 mediate	 viral	
entry.	Cell	host	&	microbe.	2011;9(4):286‐98.	
55.	 Scott	RS,	McMahon	EJ,	Pop	SM,	Reap	EA,	Caricchio	R,	Cohen	PL,	et	al.	Phagocytosis	and	clearance	
of	apoptotic	cells	is	mediated	by	MER.	Nature.	2001;411(6834):207‐11.	
56.	 Zagorska	A,	Traves	PG,	Lew	ED,	Dransfield	I,	Lemke	G.	Diversification	of	TAM	receptor	tyrosine	
kinase	function.	Nature	immunology.	2014;15(10):920‐8.	
57.	 D'Cruz	 PM,	 Yasumura	D,	Weir	 J,	Matthes	MT,	 Abderrahim	H,	 LaVail	MM,	 et	 al.	Mutation	 of	 the	
receptor	 tyrosine	 kinase	 gene	 Mertk	 in	 the	 retinal	 dystrophic	 RCS	 rat.	 Human	 molecular	 genetics.	
2000;9(4):645‐51.	
58.	 Xiong	W,	Chen	Y,	Wang	H,	Wang	H,	Wu	H,	Lu	Q,	et	al.	Gas6	and	the	Tyro	3	receptor	tyrosine	kinase	
subfamily	regulate	the	phagocytic	function	of	Sertoli	cells.	Reproduction.	2008;135(1):77‐87.	
  37
59.	 Graham	 DK,	 DeRyckere	 D,	 Davies	 KD,	 Earp	 HS.	 The	 TAM	 family:	 phosphatidylserine	 sensing	
receptor	tyrosine	kinases	gone	awry	in	cancer.	Nature	reviews	Cancer.	2014;14(12):769‐85.	
60.	 Loges	S,	Schmidt	T,	Tjwa	M,	van	Geyte	K,	Lievens	D,	Lutgens	E,	et	al.	Malignant	cells	 fuel	 tumor	
growth	by	educating	infiltrating	leukocytes	to	produce	the	mitogen	Gas6.	Blood.	2010;115(11):2264‐73.	
61.	 Robins	RS,	Lemarie	CA,	Laurance	S,	Aghourian	MN,	Wu	J,	Blostein	MD.	Vascular	Gas6	contributes	
to	 thrombogenesis	 and	 promotes	 tissue	 factor	 up‐regulation	 after	 vessel	 injury	 in	 mice.	 Blood.	
2013;121(4):692‐9.	
62.	 Springer	TA.	Traffic	signals	for	lymphocyte	recirculation	and	leukocyte	emigration:	the	multistep	
paradigm.	Cell.	1994;76(2):301‐14.	
63.	 Hogg	 N,	 Berlin	 C.	 Structure	 and	 function	 of	 adhesion	 receptors	 in	 leukocyte	 trafficking.	
Immunology	today.	1995;16(7):327‐30.	
64.	 Zhang	 F,	 Yu	W,	 Hargrove	 JL,	 Greenspan	 P,	 Dean	 RG,	 Taylor	 EW,	 et	 al.	 Inhibition	 of	 TNF‐alpha	
induced	ICAM‐1,	VCAM‐1	and	E‐selectin	expression	by	selenium.	Atherosclerosis.	2002;161(2):381‐6.	
65.	 Tjwa	M,	Bellido‐Martin	L,	Lin	Y,	Lutgens	E,	Plaisance	S,	Bono	F,	et	al.	Gas6	promotes	inflammation	
by	enhancing	interactions	between	endothelial	cells,	platelets,	and	leukocytes.	Blood.	2008;111(8):4096‐
105.	
66.	 Avanzi	GC,	Gallicchio	M,	Bottarel	F,	Gammaitoni	L,	Cavalloni	G,	Buonfiglio	D,	et	al.	GAS6	inhibits	
granulocyte	adhesion	to	endothelial	cells.	Blood.	1998;91(7):2334‐40.	
67.	 Cavet	ME,	Smolock	EM,	Ozturk	OH,	World	C,	Pang	J,	Konishi	A,	et	al.	Gas6‐axl	receptor	signaling	is	
regulated	by	glucose	in	vascular	smooth	muscle	cells.	Arteriosclerosis,	thrombosis,	and	vascular	biology.	
2008;28(5):886‐91.	
68.	 Cross	MJ,	Dixelius	J,	Matsumoto	T,	Claesson‐Welsh	L.	VEGF‐receptor	signal	transduction.	Trends	
in	biochemical	sciences.	2003;28(9):488‐94.	
69.	 Pandya	 NM,	 Dhalla	 NS,	 Santani	 DD.	 Angiogenesis‐‐a	 new	 target	 for	 future	 therapy.	 Vascular	
pharmacology.	2006;44(5):265‐74.	
70.	 Holland	 SJ,	 Powell	MJ,	 Franci	 C,	 Chan	 EW,	 Friera	 AM,	 Atchison	RE,	 et	 al.	Multiple	 roles	 for	 the	
receptor	tyrosine	kinase	axl	in	tumor	formation.	Cancer	research.	2005;65(20):9294‐303.	
71.	 Ruan	GX,	Kazlauskas	A.	Axl	is	essential	for	VEGF‐A‐dependent	activation	of	PI3K/Akt.	The	EMBO	
journal.	2012;31(7):1692‐703.	
72.	 Gallicchio	M,	Mitola	S,	Valdembri	D,	Fantozzi	R,	Varnum	B,	Avanzi	GC,	et	al.	Inhibition	of	vascular	
endothelial	growth	factor	receptor	2‐mediated	endothelial	cell	activation	by	Axl	tyrosine	kinase	receptor.	
Blood.	2005;105(5):1970‐6.	
73.	 Fraineau	 S,	 Monvoisin	 A,	 Clarhaut	 J,	 Talbot	 J,	 Simonneau	 C,	 Kanthou	 C,	 et	 al.	 The	 vitamin	 K‐
dependent	anticoagulant	factor,	protein	S,	inhibits	multiple	VEGF‐A‐induced	angiogenesis	events	in	a	Mer‐	
and	SHP2‐dependent	manner.	Blood.	2012;120(25):5073‐83.	
74.	 Png	 KJ,	 Halberg	 N,	 Yoshida	 M,	 Tavazoie	 SF.	 A	 microRNA	 regulon	 that	 mediates	 endothelial	
recruitment	and	metastasis	by	cancer	cells.	Nature.	2012;481(7380):190‐4.	
75.	 Healy	AM,	Schwartz	 JJ,	Zhu	X,	Herrick	BE,	Varnum	B,	Farber	HW.	Gas	6	promotes	Axl‐mediated	
survival	 in	 pulmonary	 endothelial	 cells.	 American	 journal	 of	 physiology	 Lung	 cellular	 and	 molecular	
physiology.	2001;280(6):L1273‐81.	
76.	 Hasanbasic	 I,	 Cuerquis	 J,	 Varnum	 B,	 Blostein	 MD.	 Intracellular	 signaling	 pathways	 involved	 in	
Gas6‐Axl‐mediated	 survival	 of	 endothelial	 cells.	 American	 journal	 of	 physiology	 Heart	 and	 circulatory	
physiology.	2004;287(3):H1207‐13.	
77.	 Papapetropoulos	 A,	 Fulton	 D,	 Mahboubi	 K,	 Kalb	 RG,	 O'Connor	 DS,	 Li	 F,	 et	 al.	 Angiopoietin‐1	
inhibits	 endothelial	 cell	 apoptosis	 via	 the	 Akt/survivin	 pathway.	 The	 Journal	 of	 biological	 chemistry.	
2000;275(13):9102‐5.	
78.	 Stenhoff	 J,	Dahlback	B,	Hafizi	S.	Vitamin	K‐dependent	Gas6	activates	ERK	kinase	and	stimulates	
growth	of	cardiac	fibroblasts.	Biochemical	and	biophysical	research	communications.	2004;319(3):871‐8.	
  38
79.	 Dahlback	B.	Purification	of	human	vitamin	K‐dependent	protein	S	and	 its	 limited	proteolysis	by	
thrombin.	The	Biochemical	journal.	1983;209(3):837‐46.	
80.	 McColl	 A,	 Bournazos	 S,	 Franz	 S,	 Perretti	M,	Morgan	BP,	Haslett	 C,	 et	 al.	 Glucocorticoids	 induce	
protein	 S‐dependent	 phagocytosis	 of	 apoptotic	 neutrophils	 by	 human	 macrophages.	 Journal	 of	
immunology.	2009;183(3):2167‐75.	
81.	 Li	 YH,	 Teng	 JK,	 Tsai	WC,	 Tsai	 LM,	 Lin	 LJ,	 Chen	 JH.	 Elevation	 of	 soluble	 adhesion	molecules	 is	
associated	with	the	severity	of	myocardial	damage	in	acute	myocardial	infarction.	The	American	journal	of	
cardiology.	1997;80(9):1218‐21.	
82.	 Francisco‐Cruz	A,	Aguilar‐Santelises	M,	Ramos‐Espinosa	O,	Mata‐Espinosa	D,	Marquina‐Castillo	B,	
Barrios‐Payan	J,	et	al.	Granulocyte‐macrophage	colony‐stimulating	factor:	not	just	another	haematopoietic	
growth	factor.	Medical	oncology.	2014;31(1):774.	
83.	 Clauser	S,	Peyrard	S,	Gaussem	P,	Crespin	M,	Emmerich	J,	Aiach	M,	et	al.	Development	of	a	novel	
immunoassay	for	the	assessment	of	plasma	Gas6	concentrations	and	their	variation	with	hormonal	status.	
Clinical	chemistry.	2007;53(10):1808‐13.	
84.	 Ekman	C,	Linder	A,	Akesson	P,	Dahlback	B.	Plasma	concentrations	of	Gas6	(growth	arrest	specific	
protein	 6)	 and	 its	 soluble	 tyrosine	 kinase	 receptor	 sAxl	 in	 sepsis	 and	 systemic	 inflammatory	 response	
syndromes.	Critical	care.	2010;14(4):R158.	
85.	 Hung	YJ,	Lee	CH,	Chu	NF,	Shieh	YS.	Plasma	protein	growth	arrest‐specific	6	levels	are	associated	
with	 altered	 glucose	 tolerance,	 inflammation,	 and	 endothelial	 dysfunction.	 Diabetes	 care.	
2010;33(8):1840‐4.	
86.	 Dang	CT,	Magid	MS,	Weksler	B,	Chadburn	A,	Laurence	 J.	Enhanced	endothelial	 cell	apoptosis	 in	
splenic	tissues	of	patients	with	thrombotic	thrombocytopenic	purpura.	Blood.	1999;93(4):1264‐70.	
87.	 Kockx	MM,	Herman	AG.	Apoptosis	 in	 atherosclerosis:	 beneficial	 or	detrimental?	Cardiovascular	
research.	2000;45(3):736‐46.	
88.	 Lee	 SD,	 Shroyer	KR,	Markham	NE,	 Cool	 CD,	Voelkel	NF,	 Tuder	RM.	Monoclonal	 endothelial	 cell	
proliferation	 is	 present	 in	 primary	 but	 not	 secondary	 pulmonary	 hypertension.	 The	 Journal	 of	 clinical	
investigation.	1998;101(5):927‐34.	
  39
6. Acknowledgments 
I would like to take this opportunity to thank Kaisa Otteby for giving me great support 
during this year. I would like to express my gratitude for her patience, never-ending 
enthusiasm, and for teaching me various techniques. Finally, I would like to thank Kaisa for 
showing me the joy of science and for encouraging and supporting me in developing my 
ideas.  
I would like to greatly acknowledge Björn Dahlbäck for giving me an outstanding chance to 
join his group for over a year. I am very grateful for sharing his enormous knowledge and for 
his great help in reaching my dream to become a scientist. I would also like to thank Björn for 
being a role model to me both as a great scientist and as a person.  
I also thank Cecilia Frej and Mario Ruiz-Garcia for giving me useful advices, teaching me 
many techniques and showing me great support. 
Last but not least, I would like to thank the rest of the Björn's group for many memorable 
moments, help and a friendly atmosphere. Being a part of this group was a great pleasure for 
me. 
 
POPULAR SCIENCE SUMMARY 
Oktawia Wolanin 
   
Advisor: Kaisa Otteby 
Master’s Degree Project in Molecular Biology 60 credits 2015 
Department of Biology, Lund University 
40
 
TAMing endothelial inflammation 
TAM (Tyro3, Axl and Mer) receptors are some of the proteins attached to the cell surface. In the 
presented work we show an important role of these proteins in cells, which line up inner part of 
blood vessels (endothelial cells). We found that Axl and Mer play opposite roles. Axl receptor 
increases inflammation in these cells, whereas Mer decreases inflammation.   
The human cell is a very complex structure, with many proteins attached to its surface, referred to as 
cell receptors. There are many different kinds of receptors, and one group of them is the TAM 
receptors-family, which stands for Tyro3, Axl and Mer. They share structural similarities, however 
their abundance and functions vary from cell to cell. In order to activate the TAM receptor, a so called 
“TAM receptor ligand” must bind to it (Figure 1).  
TAM receptors are involved in various processes in the human body, such as clearance of dying cells. 
In this process, specialized immune cells, thanks to TAM receptors on their surface, recognize dying 
cells and “eat” them. This process is determined by TAM-ligand interaction, where the ligand binds to 
specific signals expressed on the dying cell, thus creating 
a “bridge” between both cells (Figure 1).  
TAM receptors in endothelium- are they good or bad 
players? 
TAM receptors are also expressed in endothelial cells, which line 
up the inner part of blood vessels, hence they are in direct 
contact with blood. There are many causes of inflammation in 
the human body, such as injuries and infections. Upon the 
inflammation, endothelial cells produce various proteins, which 
allow immune cells to become activated and help them pass 
through the blood vessel wall to reach the underlying tissue.  
We have measured how the different TAMs regulate various 
proteins expressed by endothelial cells during inflammatory 
conditions. Previously published studies have reached opposing 
conclusions regarding the pro or anti-inflammatory role of 
TAMs in endothelium. We observed that Axl-activation seems to 
promote inflammation, whereas Mer-activation down-regulates 
it. This observation brought new light on their role in vascular 
inflammation, which could be both good and bad. Further, we tested different pro- and 
anti-inflammatory agents, which were reported to strongly induce TAM expression in immune cells. 
To our surprise, these agents did not affect the expression of TAM receptors in human endothelial 
cells. This conclusion led us to hypothesize that TAM expression is regulated differently depending on 
cell type.  
 
Our study provides another step on the way to better understanding these receptors for future 
therapeutic use. 
Our results provide the confirmation of pro-inflammatory properties of Axl in endothelium, thus 
suggesting this receptor as an interesting drug target for fighting inflammation.  
 
Figure 1 TAM receptors-ligand 
interaction (Lemke & Rothlin. 
Nature reviews Immunology. 
2008;8(5):327-36, modified). 
  
	
 
